Bioweapon. Guess where they develop that! In the Ukraine...
Choice of Full-length #Spike Protein by Competing Companies as Sole COVID "Vaccine" Target Reveals #Bioweapon Operation: #Dr. #Mike #Yeadon
There could be no worse jab antigen pick: toxic, rapidly mutating to escape vaccinal immunity, and having humanlike protein sequences to provoke autoimmunity, says Pfizer ex-boss.
"In a video interview, Pfizer’s former respiratory medicine chief Michael Yeadon PhD decries singular use of the SARS-CoV-2 viral spike protein for Covid vaccines as highly toxic, rapidly mutating to enable vaccinal immune escape, and containing too many human-like amino acid sequences, provoking autoimmune reactions in many injectees.
In agreement, this newsletter has noted potentially deadly design features of current Covid vaccines and the incredible 'coincidence' in the awful 'choice' of full-length spike protein targeting by multiple vaccine companies.
These are signs Covid is a bioweapon operation…"
???? Read more: Dr. James Hill


Bioweapon. Guess where they develop that! In the Ukraine... Choice of Full-length #Spike Protein by Competing Companies as Sole COVID "Vaccine" Target Reveals #Bioweapon Operation: #Dr. #Mike #Yeadon There could be no worse jab antigen pick: toxic, rapidly mutating to escape vaccinal immunity, and having humanlike protein sequences to provoke autoimmunity, says Pfizer ex-boss. "In a video interview, Pfizer’s former respiratory medicine chief Michael Yeadon PhD decries singular use of the SARS-CoV-2 viral spike protein for Covid vaccines as highly toxic, rapidly mutating to enable vaccinal immune escape, and containing too many human-like amino acid sequences, provoking autoimmune reactions in many injectees. In agreement, this newsletter has noted potentially deadly design features of current Covid vaccines and the incredible 'coincidence' in the awful 'choice' of full-length spike protein targeting by multiple vaccine companies. These are signs Covid is a bioweapon operation…" ???? Read more: Dr. James Hill
0 Comments 0 Shares 764 Views